¿Qué hemos aprendido en estos dos años del manejo del paciente con Cáncer de Pulmón No Microcítico en segunda línea de tratamiento con Inmunoterapia?

14 / 27

• Improved OS with atezolizumab
vs docetaxel was observed at
1, 2 and 3 years
• ORR with both atezolizumab and
docetaxel was 15%
• Median duration of response:
− Atezolizumab: 22.3 mo (range 2.9 to 38.7+)
− Docetaxel: 7.2 mo (range, 1.5+ to 15.4)
• Treatment-related Grade 3-4 AEs:
− Atezolizumab: 14%
− Docetaxel: 40%
3-year OS
19%
10%
2-year OS
32%
17%
1-year OS
52%
42%
Landmark overall survival and duration of response
in POPLAR
+ denotes a censored value.
Data cutoff: 7 April, 2017
Park, et al. WCLC 2017 14